Home › Cystic Fibrosis › NCT01852448
Genetics of Insulin and Incretins in Cystic Fibrosis
Evaluation of the Enteroinsular Axis in Cystic Fibrosis
Who can join
Ages 2 and older · All sexes
Full eligibility criteria
Inclusion Criteria 1. Subjects age \>2y 2. Diagnosis of Cystic Fibrosis 3. For subjects\< 18 years, parental/guardian permission (informed consent) and if appropriate, child assent Exclusion Criteria 1. Established diagnosis of non-CFRD (cystic fibrosis related diabetes) (e.g T1DM) .
About the study
Cystic fibrosis related diabetes (CFRD) is associated with worse CF-relevant outcomes.
The mechanisms underlying CFRD development are not fully understood, but recent evidence suggests Type 2 Diabetes Mellitus (T2DM) mechanisms may be involved and may involve incretins (gut secreted hormones that augment insulin secretion in response to a nutrient load).
This study will examine the prevalence of Genome wide association study (GWAS)-implicated T2DM alleles (including TCF7L2) across the spectrum of glucose abnormalities in CF and will use this information to compare incretin and insulin secretion in non-diabetic children and adults with high risk and low risk alleles.
What is being tested
- Blood or Saliva Sample Collection (genetic)
Sponsor: Children's Hospital of Philadelphia · Participants: 550 · Started: 2013-05
Contact the study team
- Rachel Walega · Phone: 267-586-5969
Official record on ClinicalTrials.gov — NCT01852448
Locations in the U.S.
| Pennsylvania | The Children's Hopsital of Philadelphia, Philadelphia The University of Pennsylvania, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.